Accelerates healing of tendon, ligament, muscle, and bone injuries.
Why this rating
This is the claim BPC-157 is sold on, and the animal evidence behind it is genuinely extensive and consistent across many independent laboratories. It stays at preclinical because a 2025 systematic review of the whole literature through June 2024 found 36 studies, of which 35 were in animals and 1 was clinical. Consistent animal healing data has a poor record of predicting human musculoskeletal outcomes, and the review itself concluded the compound should not be recommended clinically until human trials exist.
Supporting studies
- HSS Journal2025
35 of 36 identified studies were preclinical. No adequately powered human efficacy trial exists.